Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen

Key Points

• Pyxis Oncology received an upgrade from a "sell" to a "hold" rating by Wall Street Zen, indicating increased confidence in the stock's performance.
• The stock currently has a consensus target price of $8.67, with three analysts rating it a "Buy" and two a "Hold".
• Pyxis Oncology reported an earnings per share of ($0.30) for the last quarter, surpassing analysts' expectations and showing potential for growth.

Wall Street Zen upgraded shares of Pyxis Oncology (NASDAQ:PYXS - Free Report) from a sell rating to a hold rating in a research report sent to investors on Sunday morning.

Other equities analysts also recently issued research reports about the company. Zacks Research raised Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.67.

Pyxis Oncology Price Performance

Shares of PYXS stock traded down $0.05 during trading hours on Friday, reaching $1.28. 152,995 shares of the company traded hands, compared to its average volume of 465,347. The company has a market cap of $79.39 million, a P/E ratio of -0.80 and a beta of 1.13. The firm has a 50-day moving average price of $1.18 and a 200 day moving average price of $1.15. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.06. The company had revenue of $2.82 million for the quarter. Sell-side analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of hedge funds have recently made changes to their positions in PYXS. Millennium Management LLC increased its position in Pyxis Oncology by 53.8% during the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock valued at $4,650,000 after buying an additional 1,043,228 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Pyxis Oncology by 36.6% in the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock valued at $106,000 after purchasing an additional 18,128 shares during the period. ProShare Advisors LLC acquired a new stake in Pyxis Oncology during the fourth quarter worth about $26,000. Ameriprise Financial Inc. acquired a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. Finally, Caption Management LLC acquired a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.